RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
Filed with ASX · · 2 pages · English
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
- RAD Doses First Patient in RAD 402 Phase 1 Clinical Study
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
Later from Radiopharm Theranostics
- Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
- RAD Completes Enrollment in Phase 2b Trial of RAD 101
- Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
- Radiopharm Theranostics Reports Business Update
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics